GT201000172A - Inhibidores de cinesina como productos terapéuticos para el cáncer - Google Patents
Inhibidores de cinesina como productos terapéuticos para el cáncerInfo
- Publication number
- GT201000172A GT201000172A GT201000172A GT201000172A GT201000172A GT 201000172 A GT201000172 A GT 201000172A GT 201000172 A GT201000172 A GT 201000172A GT 201000172 A GT201000172 A GT 201000172A GT 201000172 A GT201000172 A GT 201000172A
- Authority
- GT
- Guatemala
- Prior art keywords
- inhibitors
- cinesine
- cancer
- compounds
- ksp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA INVENCIÓN PROPORCIONA NOVEDOSOS COMPUESTOS DE IMIDAZOL QUE INHIBEN LA ACTIVIDAD DE LA PROTEÍNA DE HUSO DE CINESINA (KSP, TAMBIÉN DENOMINADA COMO EG5). LOS INHIBIDORES DE KSP PUEDEN REDUCIR LA PROLIFERACIÓN CELULAR INDESEADA, Y PROPORCIONAN OTROS EFECTOS TERAPÉUTICOS. LA INVENCIÓN TAMBIÉN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN ESTOS COMPUESTOS NOVEDOSOS, Y MÉTODOS PARA UTILIZAR LOS INHIBIDORES DE KSP NOVEDOSOS Y SUS COMPOSICIONES FAMRACÉUTICAS PARA TRATAR DIFERENTES TIPOS DE CÁNCERES. LOS COMPUESTOS, COMPOSICIONES Y MÉTODOS DE LA INVENCIÓN SON EN ESPECIAL ÚTILES PARA EL TRATAMIENTO DE CIERTAS CLASES DE CÁNCERES QUE SON RESISTENTES A LOS TRATAMIENTOS CON FÁRMACOS CONVENCIONALES, DEBIDO A QUE SE MUESTRA QUE ESTOS CÁNCERES SIGUEN SIENDO SENSIBLES A LOS COMPUESTOS DE LA INVENCIÓN.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1396607P | 2007-12-14 | 2007-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201000172A true GT201000172A (es) | 2012-04-30 |
Family
ID=40328566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201000172A GT201000172A (es) | 2007-12-14 | 2010-06-14 | Inhibidores de cinesina como productos terapéuticos para el cáncer |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8252832B2 (es) |
| EP (1) | EP2229170B1 (es) |
| JP (1) | JP5501976B2 (es) |
| KR (1) | KR20100098394A (es) |
| CN (1) | CN101939005B (es) |
| AR (1) | AR069676A1 (es) |
| AU (1) | AU2008337570B2 (es) |
| BR (1) | BRPI0821248A2 (es) |
| CA (1) | CA2708822A1 (es) |
| CL (1) | CL2008003707A1 (es) |
| CO (1) | CO6290651A2 (es) |
| CR (1) | CR11412A (es) |
| DO (1) | DOP2010000175A (es) |
| EA (1) | EA018014B1 (es) |
| EC (1) | ECSP10010248A (es) |
| ES (1) | ES2459442T3 (es) |
| GE (1) | GEP20125647B (es) |
| GT (1) | GT201000172A (es) |
| IL (1) | IL205831A0 (es) |
| MA (1) | MA31872B1 (es) |
| MY (1) | MY150214A (es) |
| NI (1) | NI201000091A (es) |
| NZ (1) | NZ585142A (es) |
| PA (1) | PA8807801A1 (es) |
| PE (1) | PE20091451A1 (es) |
| SM (1) | SMP201000095B (es) |
| TN (1) | TN2010000204A1 (es) |
| TW (1) | TW200930704A (es) |
| UY (1) | UY31532A1 (es) |
| WO (1) | WO2009077448A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
| US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
| US8748626B2 (en) | 2010-04-15 | 2014-06-10 | Novartis Ag | Oxazole and thiazole compounds as KSP inhibitors |
| JP2016516035A (ja) * | 2013-03-15 | 2016-06-02 | ノバルティス アーゲー | 細胞増殖阻害剤およびそれらのコンジュゲート |
| US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| CA2990076A1 (en) * | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| CN105418527A (zh) * | 2015-12-28 | 2016-03-23 | 青岛友诚高新技术有限公司 | 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途 |
| CN105646361B (zh) * | 2016-02-17 | 2017-12-01 | 吉首大学 | 一种2,4,5‑三芳基咪唑型化合物及其制法和用途 |
| IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
| CN106668863B (zh) * | 2017-02-21 | 2019-04-23 | 南方医科大学 | 靶向ktn1治疗皮肤鳞状细胞癌的药物 |
| GB201706162D0 (en) * | 2017-04-19 | 2017-05-31 | Nat Univ Singapore | Compounds |
| WO2019196111A1 (zh) * | 2018-04-13 | 2019-10-17 | 上海交通大学医学院附属瑞金医院 | 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物 |
| CN109646679A (zh) * | 2019-01-28 | 2019-04-19 | 中国科学院长春应用化学研究所 | 铁离子螯合剂及其可药用盐的用途 |
| CN111529526B (zh) * | 2020-04-14 | 2021-04-23 | 广州领晟医疗科技有限公司 | 一种化合物在制备治疗急性胰腺炎的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0510929A (pt) * | 2004-06-18 | 2007-07-17 | Chiron Corp | derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer |
| US7271271B2 (en) | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
| MY147188A (en) | 2005-08-09 | 2012-11-14 | Novartis Ag | Substituted imidazole compounds as ksp inhibitors |
| US7820646B2 (en) | 2007-01-05 | 2010-10-26 | Novartis Vaccines And Diagnostics, Inc. | Cyclized derivatives as Eg-5 inhibitors |
-
2008
- 2008-11-25 US US12/313,923 patent/US8252832B2/en not_active Expired - Fee Related
- 2008-12-12 BR BRPI0821248-1A patent/BRPI0821248A2/pt not_active IP Right Cessation
- 2008-12-12 GE GEAP200811846A patent/GEP20125647B/en unknown
- 2008-12-12 CN CN200880120667.8A patent/CN101939005B/zh not_active Expired - Fee Related
- 2008-12-12 WO PCT/EP2008/067412 patent/WO2009077448A1/en active Application Filing
- 2008-12-12 ES ES08863009.0T patent/ES2459442T3/es active Active
- 2008-12-12 EP EP08863009.0A patent/EP2229170B1/en active Active
- 2008-12-12 EA EA201000900A patent/EA018014B1/ru not_active IP Right Cessation
- 2008-12-12 KR KR1020107012912A patent/KR20100098394A/ko not_active Application Discontinuation
- 2008-12-12 MY MYPI2010002030A patent/MY150214A/en unknown
- 2008-12-12 AR ARP080105410A patent/AR069676A1/es not_active Application Discontinuation
- 2008-12-12 CA CA2708822A patent/CA2708822A1/en not_active Abandoned
- 2008-12-12 AU AU2008337570A patent/AU2008337570B2/en not_active Ceased
- 2008-12-12 NZ NZ585142A patent/NZ585142A/en not_active IP Right Cessation
- 2008-12-12 TW TW097148535A patent/TW200930704A/zh unknown
- 2008-12-12 PE PE2008002064A patent/PE20091451A1/es not_active Application Discontinuation
- 2008-12-12 CL CL2008003707A patent/CL2008003707A1/es unknown
- 2008-12-12 PA PA20088807801A patent/PA8807801A1/es unknown
- 2008-12-12 JP JP2010537460A patent/JP5501976B2/ja not_active Expired - Fee Related
- 2008-12-15 UY UY31532A patent/UY31532A1/es not_active Application Discontinuation
-
2010
- 2010-05-05 CR CR11412A patent/CR11412A/es not_active Application Discontinuation
- 2010-05-07 TN TN2010000204A patent/TN2010000204A1/fr unknown
- 2010-05-17 IL IL205831A patent/IL205831A0/en unknown
- 2010-05-31 MA MA32879A patent/MA31872B1/fr unknown
- 2010-06-02 NI NI201000091A patent/NI201000091A/es unknown
- 2010-06-10 CO CO10070369A patent/CO6290651A2/es not_active Application Discontinuation
- 2010-06-11 DO DO2010000175A patent/DOP2010000175A/es unknown
- 2010-06-14 GT GT201000172A patent/GT201000172A/es unknown
- 2010-06-14 EC EC2010010248A patent/ECSP10010248A/es unknown
- 2010-07-13 SM SM201000095T patent/SMP201000095B/it unknown
-
2012
- 2012-07-11 US US13/546,713 patent/US8664256B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201000172A (es) | Inhibidores de cinesina como productos terapéuticos para el cáncer | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP22029777A (es) | Heterociclos bic?clicos como inhibidores de fgfr | |
| GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
| EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
| ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
| CO6710897A2 (es) | Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer | |
| CL2008003873A1 (es) | Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| EA201792286A1 (ru) | Способы лечения рака | |
| BR112022010054A2 (pt) | Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso | |
| ECSP22098041A (es) | Inhibidores alostéricos de egfr y métodos de uso de estos | |
| CU20100121A7 (es) | Inhibidores de cinesina como productos terapéuticos para el cáncer | |
| CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CL2022000217A1 (es) | Inhibidores de enzimas | |
| AR117459A1 (es) | Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos | |
| CR20190110A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| DOP2009000143A (es) | Quinazolinas para la inhibicion de pdk1 |